A detailed history of Tower Bridge Advisors transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Tower Bridge Advisors holds 32,288 shares of BMY stock, worth $1.86 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
32,288
Previous 32,890 1.83%
Holding current value
$1.86 Million
Previous $1.37 Billion 22.3%
% of portfolio
0.17%
Previous 0.15%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$39.66 - $51.75 $23,875 - $31,153
-602 Reduced 1.83%
32,288 $1.67 Billion
Q2 2024

Jul 24, 2024

SELL
$40.25 - $52.99 $297,246 - $391,331
-7,385 Reduced 18.34%
32,890 $1.37 Billion
Q1 2024

Apr 29, 2024

SELL
$47.98 - $54.4 $57,192 - $64,844
-1,192 Reduced 2.87%
40,275 $2.18 Billion
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $332,233 - $396,446
-6,853 Reduced 14.18%
41,467 $2.13 Billion
Q3 2023

Nov 01, 2023

SELL
$57.89 - $64.73 $631,116 - $705,686
-10,902 Reduced 18.41%
48,320 $2.8 Billion
Q2 2023

Jul 20, 2023

SELL
$63.71 - $70.74 $1.98 Million - $2.2 Million
-31,105 Reduced 34.44%
59,222 $3.79 Billion
Q1 2023

Apr 26, 2023

SELL
$65.71 - $74.53 $24,444 - $27,725
-372 Reduced 0.41%
90,327 $6.26 Billion
Q4 2022

Jan 27, 2023

SELL
$68.48 - $81.09 $1,848 - $2,189
-27 Reduced 0.03%
90,699 $6.53 Billion
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $88 - $52,097
-678 Reduced 0.74%
90,726 $6.45 Billion
Q2 2022

Jul 21, 2022

SELL
$72.62 - $79.98 $163,031 - $179,555
-2,245 Reduced 2.4%
91,404 $7.04 Billion
Q1 2022

May 05, 2022

SELL
$61.48 - $73.72 $341,890 - $409,956
-5,561 Reduced 5.61%
93,649 $6.84 Billion
Q4 2021

Feb 09, 2022

SELL
$53.63 - $62.52 $433,330 - $505,161
-8,080 Reduced 7.53%
99,210 $6.19 Billion
Q3 2021

Oct 28, 2021

SELL
$59.17 - $69.31 $129,700 - $151,927
-2,192 Reduced 2.0%
107,290 $6.35 Billion
Q2 2021

Aug 10, 2021

SELL
$61.91 - $67.42 $722,675 - $786,993
-11,673 Reduced 9.63%
109,482 $7.32 Billion
Q1 2021

May 12, 2021

SELL
$59.34 - $66.74 $4.09 Million - $4.6 Million
-68,859 Reduced 36.24%
121,155 $7.65 Billion
Q4 2020

Feb 11, 2021

BUY
$57.74 - $65.43 $1.5 Million - $1.7 Million
25,920 Added 15.8%
190,014 $11.8 Billion
Q3 2020

Nov 13, 2020

BUY
$57.43 - $63.64 $693,696 - $768,707
12,079 Added 7.95%
164,094 $9.89 Billion
Q2 2020

Jul 22, 2020

BUY
$54.82 - $64.09 $108,927 - $127,346
1,987 Added 1.32%
152,015 $8.94 Billion
Q1 2020

Apr 27, 2020

BUY
$46.4 - $67.43 $234,320 - $340,521
5,050 Added 3.48%
150,028 $8.36 Billion
Q4 2019

Feb 05, 2020

SELL
$49.21 - $64.19 $111,755 - $145,775
-2,271 Reduced 1.54%
144,978 $9.31 Billion
Q3 2019

Nov 12, 2019

SELL
$42.77 - $50.71 $615,759 - $730,071
-14,397 Reduced 8.91%
147,249 $8.54 Billion
Q2 2019

Aug 06, 2019

SELL
$44.62 - $49.34 $1.07 Million - $1.18 Million
-23,978 Reduced 12.92%
161,646 $7.33 Billion
Q1 2019

Apr 30, 2019

BUY
$45.12 - $53.8 $1.16 Million - $1.39 Million
25,776 Added 16.13%
185,624 $8.86 Billion
Q4 2018

Feb 07, 2019

BUY
$48.76 - $63.23 $1.49 Million - $1.93 Million
30,558 Added 23.64%
159,848 $8.31 Billion
Q3 2018

Oct 23, 2018

SELL
$55.19 - $62.25 $41,613 - $46,936
-754 Reduced 0.58%
129,290 $8.03 Billion
Q2 2018

Aug 09, 2018

SELL
$50.53 - $62.98 $228,648 - $284,984
-4,525 Reduced 3.36%
130,044 $7.2 Billion
Q1 2018

May 02, 2018

SELL
$59.92 - $68.98 $3.53 Million - $4.07 Million
-58,950 Reduced 30.46%
134,569 $8.51 Billion
Q4 2017

Jan 30, 2018

SELL
$59.94 - $65.35 $181,678 - $198,075
-3,031 Reduced 1.54%
193,519 $11.9 Billion
Q3 2017

Nov 06, 2017

BUY
$55.23 - $63.74 $10.9 Million - $12.5 Million
196,550
196,550 $12.5 Billion

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Tower Bridge Advisors Portfolio

Follow Tower Bridge Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Bridge Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Tower Bridge Advisors with notifications on news.